Literature DB >> 15218474

Resveratrol, a red wine polyphenol, protects spinal cord from ischemia-reperfusion injury.

Ugursay Kiziltepe1, N Nilufer D Turan, Unsal Han, A Tulga Ulus, Fatma Akar.   

Abstract

OBJECTIVE: The cardioprotective effect of red wine has been attributed to resveratrol. The resveratrol-induced protection against ischemia-reperfusion (I/R) injury has been documented in heart, kidney, and brain. Resveratrol scavenges free O(2) radicals and upregulates nitric oxide (NO). However, the presence of resveratrol-induced spinal cord protection against I/R injury has not been reported in the literature. The objective of this study was to evaluate the effects of resveratrol on neurologic functions, histopathologic changes, and NO metabolism following temporary spinal cord ischemia (SCI) in rabbits. Material and methods SCI was induced with occlusion of the infrarenal aorta in rabbits. In addition to the sham group (group S, n = 7), group C (n = 7) received vehicle 30 minutes before ischemia. Group R1 (n = 7) and R10 (n = 7) received 1 mg/kg and 10 mg/kg resveratrol instead of vehicle, respectively. Blood samples were taken to obtain nitrite/nitrate levels during the surgical procedure. After neurologic evaluation at the 48th hour of reperfusion, lumbar spinal cords were removed for histopathologic examination and malondialdehyde measurement as a marker of oxidative stress.
RESULTS: Five animals in group C had paraplegia while 5 in group R10 had normal neurologic functions. The average Tarlov score of group R10 was significantly higher than that the score of group C (4.1 +/- 1.2, vs 1.2 +/- 2.2; P =.014). Histopathologic examination revealed higher neuronal viability index in group R10 compared with that of group C (0.82 +/- 0.24 vs. 0.46 +/- 0.34; P =.018). Nitrite/nitrate levels decreased in group C (from 357 +/- 20.15 micromol/L to 281 +/- 47.9 micromol/L; P <.01) whereas they increased both in group R1 and group R10 (from 287+/-28 micromol/L to 310 +/- 33.9 micromol/L and from 296 +/- 106 micromol/L to 339 +/- 87 micromol/L, respectively) during SCI. Malondialdehyde levels of group R10 was lower than those of group C (55 +/- 12.9 nmol/mg protein vs 83.9 +/- 15.1 nmol/mg protein; P =.001, respectively).
CONCLUSIONS: In this model of SCI, resveratrol decreased oxidative stress, increased NO release, and protected spinal cord from I/R injury. Resveratrol-induced neuroprotection is probably mediated by its antioxidant and NO promoting properties. Before considering the clinical use of this natural antioxidant, further research is warranted about its mechanism of effects, timing, and optimum dose. CLINICAL RELEVANCE: Paraplegia that results from spinal cord ischemia is a catastrophic complication of thoracic and thoracoabdominal aorta surgical procedures. Despite several surgical modifications and pharmacologic approaches, paraplegia has not been totally eliminated. On clinical grounds, the efficiency of currently used pharmacologic agents to prevent spinal cord injury during thoracic and thoracoabdominal aorta surgery is very limited and their benefit is controversial. Preischemic infusion of resveratrol protects the spinal cord from ischemia reperfusion injury in rabbits. Following clarification of the underlying protective mechanism, optimal dose, and timing, resveratrol may used in humans as an adjunct to eliminate this catastrophic complication.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15218474     DOI: 10.1016/j.jvs.2004.03.032

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  26 in total

Review 1.  Resveratrol and diabetic cardiac function: focus on recent in vitro and in vivo studies.

Authors:  Belma Turan; Erkan Tuncay; Guy Vassort
Journal:  J Bioenerg Biomembr       Date:  2012-04       Impact factor: 2.945

Review 2.  The influence of dietary factors in central nervous system plasticity and injury recovery.

Authors:  Fernando Gomez-Pinilla; Alexis G Gomez
Journal:  PM R       Date:  2011-06       Impact factor: 2.298

3.  Resveratrol attenuates behavioral impairments and reduces cortical and hippocampal loss in a rat controlled cortical impact model of traumatic brain injury.

Authors:  Richard H Singleton; Hong Q Yan; Wendy Fellows-Mayle; C Edward Dixon
Journal:  J Neurotrauma       Date:  2010-06       Impact factor: 5.269

Review 4.  Antioxidant therapies in traumatic brain and spinal cord injury.

Authors:  Mona Bains; Edward D Hall
Journal:  Biochim Biophys Acta       Date:  2011-11-04

Review 5.  The biological responses to resveratrol and other polyphenols from alcoholic beverages.

Authors:  Lindsay Brown; Paul A Kroon; Dipak K Das; Samarjit Das; Arpad Tosaki; Vincent Chan; Manfred V Singer; Peter Feick
Journal:  Alcohol Clin Exp Res       Date:  2009-06-10       Impact factor: 3.455

6.  Significance of wine and resveratrol in cardiovascular disease: French paradox revisited.

Authors:  Ramesh Vidavalur; Hajime Otani; Pawan K Singal; Nilanjana Maulik
Journal:  Exp Clin Cardiol       Date:  2006

7.  Sirt1's complex roles in neuroprotection.

Authors:  Bor Luen Tang
Journal:  Cell Mol Neurobiol       Date:  2009-12       Impact factor: 5.046

Review 8.  Wine polyphenols: potential agents in neuroprotection.

Authors:  Abdelkader Basli; Stéphanie Soulet; Nassima Chaher; Jean-Michel Mérillon; Mohamed Chibane; Jean-Pierre Monti; Tristan Richard
Journal:  Oxid Med Cell Longev       Date:  2012-07-05       Impact factor: 6.543

Review 9.  Therapeutic Effects of Resveratrol on Ischemia-Reperfusion Injury in the Nervous System.

Authors:  Alireza Sarkaki; Mojtaba Rashidi; Mina Ranjbaran; Aram Asareh Zadegan Dezfuli; Zahra Shabaninejad; Ebrahim Behzad; Maryam Adelipour
Journal:  Neurochem Res       Date:  2021-08-07       Impact factor: 3.996

10.  Protection against recurrent stroke with resveratrol: endothelial protection.

Authors:  Darren Clark; Ursula I Tuor; Roger Thompson; Adam Institoris; Angela Kulynych; Xu Zhang; David W Kinniburgh; Ferenc Bari; David W Busija; Philip A Barber
Journal:  PLoS One       Date:  2012-10-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.